Literature DB >> 10946304

Inhibition of LPS-induced cytokines by Bcl-xL in a murine macrophage cell line.

V Lakics1, A E Medvedev, S Okada, S N Vogel.   

Abstract

The antiapoptotic molecule Bcl-xL has been implicated in the differentiation and survival of activated macrophages in inflammatory conditions. In this report, the role of Bcl-xL in LPS-induced cytokine gene expression and secretion was studied. Bcl-xL-transfected RAW 264 macrophages were protected from gliotoxin-induced apoptosis, indicating the presence of functional Bcl-xL. Overexpression of Bcl-xL in this macrophage cell line was also associated with a marked inhibition of LPS-induced TNF-alpha, JE/monocyte chemoattractant protein 1, and macrophage inflammatory protein 2 secretion. Inhibition of LPS-induced cytokine secretion was paralleled by a decrease in levels of steady-state mRNA for the above cytokines and for IL-1beta. Decreased production of TNF-alpha in Bcl-xL transfectants was not due to increased mRNA degradation, as the mRNA half-lives were the same in Bcl-xL transfectants and control macrophages. Although the composition of NF-kappaB complexes detected by EMSA and supershift analysis in nuclear lysates derived from Bcl-xL transfectants and control cells was indistinguishable, LPS-induced inhibitory kappaBalpha degradation, as well as NF-kappaB binding and AP-1 activation, were slightly decreased by ectopic expression of Bcl-xL. More strikingly, LPS-induced phosphorylation of p38 mitogen-activated protein kinase and c-Jun N-terminal kinase was strongly repressed by Bcl-xL overexpression, offering a possible mechanism for the inhibition of LPS-induced cytokine production. These data provide the first evidence for a novel role for Bcl-xL as an anti-inflammatory mediator in macrophages.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10946304     DOI: 10.4049/jimmunol.165.5.2729

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Inhibition of apoptosis by Escherichia coli K1 is accompanied by increased expression of BclXL and blockade of mitochondrial cytochrome c release in macrophages.

Authors:  Sunil K Sukumaran; Suresh K Selvaraj; Nemani V Prasadarao
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

2.  Monocyte-specific Bcl-2 expression attenuates inflammation and heart failure in monocyte chemoattractant protein-1 (MCP-1)-induced cardiomyopathy.

Authors:  Jianli Niu; Asim Azfer; Pappachan E Kolattukudy
Journal:  Cardiovasc Res       Date:  2006-03-16       Impact factor: 10.787

3.  Bcl-x(L) expression in vivo in rheumatoid synovium.

Authors:  S Busteed; M W Bennett; C Molloy; A Houston; M A Stone; F Shanahan; M G Molloy; J O'Connell
Journal:  Clin Rheumatol       Date:  2006-03-30       Impact factor: 2.980

4.  Rough lipopolysaccharide from Brucella abortus and Escherichia coli differentially activates the same mitogen-activated protein kinase signaling pathways for tumor necrosis factor alpha in RAW 264.7 macrophage-like cells.

Authors:  Bruce W Jarvis; Tajie H Harris; Nilofer Qureshi; Gary A Splitter
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

5.  Analysis of NF-kappaB nuclear translocation in PMN-neutrophils of major trauma patients in the early post-traumatic period: a pilot study.

Authors:  Julia Stegmaier; Chlodwig Kirchhoff; Karl-Georg Kanz; Verena Mayer; Juergen Landes; Ekkehard Euler; Wolf Mutschler; Peter Biberthaler
Journal:  World J Surg       Date:  2006-12       Impact factor: 3.352

6.  Nuclear factor-kappa B inhibitors as potential novel anti-inflammatory agents for the treatment of immune glomerulonephritis.

Authors:  Oscar López-Franco; Yusuke Suzuki; Guillermo Sanjuán; Julia Blanco; Purificación Hernández-Vargas; Yoshikage Yo; Jeffrey Kopp; Jesús Egido; Carmen Gómez-Guerrero
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

7.  Effects of lipid administration on liver apoptotic signals in a mouse model of total parenteral nutrition (TPN).

Authors:  Yuko Tazuke; Robert A Drongowski; Imad Btaiche; Arnold G Coran; Daniel H Teitelbaum
Journal:  Pediatr Surg Int       Date:  2004-03-18       Impact factor: 1.827

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.